Japanese regulatory authorities have approved Novartis’ once-daily multiple sclerosis (MS) drug Gilenya.
The Gilenya sanction covers use of the drug for preventing relapse and delaying progression of physical disability in adult MS patients.
The only other drug licensed in Japan for preventing relapse of MS patients is interferon beta. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1309